Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
60.17
-0.47 (-0.78%)
At close: Oct 7, 2025, 4:00 PM EDT
60.00
-0.17 (-0.28%)
After-hours: Oct 7, 2025, 6:43 PM EDT

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $7.20 billion. The enterprise value is $7.33 billion.

Market Cap7.20B
Enterprise Value 7.33B

Important Dates

The next estimated earnings date is Wednesday, November 5, 2025, after market close.

Earnings Date Nov 5, 2025
Ex-Dividend Date n/a

Share Statistics

Cytokinetics has 119.66 million shares outstanding. The number of shares has increased by 16.37% in one year.

Current Share Class 119.66M
Shares Outstanding 119.66M
Shares Change (YoY) +16.37%
Shares Change (QoQ) +0.81%
Owned by Insiders (%) 0.41%
Owned by Institutions (%) 117.30%
Float 119.12M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 83.14
Forward PS 77.96
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 85.53
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.76

Current Ratio 6.76
Quick Ratio 6.61
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -5.94

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -24.87%
Return on Invested Capital (ROIC) -44.93%
Return on Capital Employed (ROCE) -49.97%
Revenue Per Employee $172,165
Profits Per Employee -$1.22M
Employee Count498
Asset Turnover 0.06
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +6.16% in the last 52 weeks. The beta is 0.68, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y) 0.68
52-Week Price Change +6.16%
50-Day Moving Average 44.62
200-Day Moving Average 41.35
Relative Strength Index (RSI) 76.07
Average Volume (20 Days) 2,538,893

Short Selling Information

The latest short interest is 14.26 million, so 11.91% of the outstanding shares have been sold short.

Short Interest 14.26M
Short Previous Month 13.83M
Short % of Shares Out 11.91%
Short % of Float 11.97%
Short Ratio (days to cover) 5.38

Income Statement

In the last 12 months, Cytokinetics had revenue of $85.74 million and -$606.31 million in losses. Loss per share was -$5.12.

Revenue85.74M
Gross Profit -304.90M
Operating Income -546.98M
Pretax Income -606.31M
Net Income -606.31M
EBITDA -537.60M
EBIT -546.98M
Loss Per Share -$5.12
Full Income Statement

Balance Sheet

The company has $858.14 million in cash and $991.76 million in debt, giving a net cash position of -$133.62 million or -$1.12 per share.

Cash & Cash Equivalents 858.14M
Total Debt 991.76M
Net Cash -133.62M
Net Cash Per Share -$1.12
Equity (Book Value) -368.72M
Book Value Per Share -3.08
Working Capital 755.48M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$426.92 million and capital expenditures -$11.80 million, giving a free cash flow of -$438.72 million.

Operating Cash Flow -426.92M
Capital Expenditures -11.80M
Free Cash Flow -438.72M
FCF Per Share -$3.67
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -637.96%
Pretax Margin -707.17%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -16.37%
Shareholder Yield -16.37%
Earnings Yield -8.42%
FCF Yield -6.09%
Dividend Details

Analyst Forecast

The average price target for Cytokinetics is $76.73, which is 27.52% higher than the current price. The consensus rating is "Buy".

Price Target $76.73
Price Target Difference 27.52%
Analyst Consensus Buy
Analyst Count 16
Revenue Growth Forecast (5Y) 143.36%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.

Last Split Date Jun 25, 2013
Split Type Reverse
Split Ratio 1:6

Scores

Cytokinetics has an Altman Z-Score of -1.99 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.99
Piotroski F-Score 3